https://scholars.lib.ntu.edu.tw/handle/123456789/580410
標題: | Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides | 作者: | Liu K.-J. Wang C.-C. Chen L.-T. ANN-LII CHENG Lin D.-T. Wu Y.-C. Yu W.-L. Hung Y.-M. Yang H.-Y. Juang S.-H. Whang-Peng J. |
公開日期: | 2004 | 卷: | 10 | 期: | 8 | 起(迄)頁: | 2645-2651 | 來源出版物: | Clinical Cancer Research | 摘要: | Purpose: We intranodally immunized metastatic colorectal carcinoma patients, who had failed standard chemotherapy, with dendritic cells (DCs) pulsed with HLA-A*0201- or HLA-A*2402-restricted carcinoembryonic antigen (CEA) peptides to evaluate the safety of this treatment and the immune response against CEA peptides before and after the treatment. Experimental Design: Six patients with the HLA-A*2402 genotype and 4 patients with the HLA-A*0201 genotype were enrolled. A single CEA peptide (YLSGANLNL) or two CEA peptides (QYSWFVNGTF and TYACFVSNL) were used for patients with the HLA-A*0201 or HLA-A*2402 genotype, respectively. Autologous DCs were generated by culturing adherent mononuclear cells with interleukin 4 and granulocyte macrophage colony-stimulating factor for 6 days. Maturation of DCs was then induced with tumor necrosis factor α for 40 h. Mature DCs were pulsed with appropriate CEA peptides for 2 h. After washing, 1 million peptide-pulsed DCs were injected into one inguinal lymph node under sonographic guidance. Each patient received four injections. Results: No grade II/III toxicity or autoimmunity was observed. An increase in the number of CEA-specific T cells after DC vaccination could be detected in 7 of 10 (70%) patients. Two (20%) patients had stable disease for at least 12 weeks. One of these 2 patients experienced a transient decrease in CEA levels during the treatment period and also had the most significant T-cell response against the immunizing CEA peptides. Conclusions: These results suggest that our vaccination procedure can generate or boost specific T-cell responses and may provide clinical benefit in certain cancer patients. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-11144355864&doi=10.1158%2f1078-0432.CCR-03-0430&partnerID=40&md5=a2786ecd6b6f093d9f8be25f9ef1fd21 https://scholars.lib.ntu.edu.tw/handle/123456789/580410 |
ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-03-0430 | SDG/關鍵字: | carcinoembryonic antigen; fluorouracil; granulocyte macrophage colony stimulating factor; HLA A antigen; interleukin 4; irinotecan; oxaliplatin; peptide derivative; threonyltyrosylalanylcysteinylphenylalanylvalylserylasparaginylleucine; tumor necrosis factor alpha; tyrosylleucylserylglycylalanylasparaginylleucylasparaginylleucine; unclassified drug; adult; aged; article; autoimmunity; cancer combination chemotherapy; cancer immunization; cancer patient; cancer staging; cell culture; cell maturation; clinical article; clinical trial; colorectal carcinoma; controlled clinical trial; controlled study; dendritic cell; drug safety; echography; female; fever; genotype; human; immune response; inguinal lymph node; male; metastasis; mononuclear cell; priority journal; side effect; statistical significance; T lymphocyte; treatment outcome; vaccination; Adult; Aged; Cancer Vaccines; Carcinoembryonic Antigen; Cells, Cultured; Colorectal Neoplasms; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Genotype; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A Antigens; Humans; Immunotherapy; Interferon Type II; Leukocytes, Mononuclear; Male; Middle Aged; Peptides; T-Lymphocytes; Time Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。